Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 2:01 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 97 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Glycopyrrolate Clear all
Terminated Early Phase 1 Interventional

Neostigmine For Snoring During DISE

NCT03316963
View directory record Official record
Conditions
Snoring
Interventions
Neostigmine Methylsulfate
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 1, 2019 · Synced Sep 3, 2026, 2:01 PM EDT
Completed Phase 4 Interventional Results available

Efficacy, Safety, and Pharmacokinetics of Sugammadex for Reversal of Neuromuscular Blockade (NMB) in Pediatric Participants (MK-8616-089)

NCT03351608
View directory record Official record
Conditions
Neuromuscular Blockade
Interventions
Sugammadex 2 mg/kg, Sugammadex 4 mg/kg, Neostigmine + Glycopyrrolate, Neostigmine + Atropine
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
2 Years to 16 Years
Enrollment
288 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
11
States / cities
Los Angeles, California • Palo Alto, California • San Diego, California + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2021 · Synced Sep 3, 2026, 2:01 PM EDT
Completed Phase 3 Interventional Results available

1-year Study to Assess the Efficacy, Safety, and Tolerability of Glycopyrronium Bromide (NVA237) in Chronic Obstructive Pulmonary Disease (COPD)

NCT00929110
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Glycopyrronium bromide, Placebo to glycopyrronium bromide, Tiotropium
Drug
Lead sponsor
Novartis
Industry
Eligibility
40 Years and older
Enrollment
1,066 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
75
States / cities
Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 68 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2012 · Synced Sep 3, 2026, 2:01 PM EDT
Completed Phase 4 Interventional Results available

Comparison of Time to Extubation Using Sugammadex or Neostigmine

NCT04606901
View directory record Official record
Conditions
Neuromuscular Blockade, Chronic Obstructive Pulmonary Disease
Interventions
neostigmine/glycopyrrolate, sugammadex
Drug
Lead sponsor
Temple University
Other
Eligibility
18 Years to 89 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 12, 2024 · Synced Sep 3, 2026, 2:01 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of QVA149 in COPD Patients

NCT02487446
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
QVA149, Umeclidinium/vilanterol, Placebo (umeclidinium/vilanterol), Placebo (QVA149)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years and older
Enrollment
357 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
58
States / cities
Andalusia, Alabama • Anniston, Alabama • Jasper, Alabama + 52 more
Source: ClinicalTrials.gov public record
Updated Dec 25, 2017 · Synced Sep 3, 2026, 2:01 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

NMBA Reversal and Postoperative Urinary Retention

NCT06948409
View directory record Official record
Conditions
Neuromuscular Blocking Agents, Urinary Retention After Procedure, Urinary Retention Postoperative, Neuromuscular Blockade Reversal Agent, Neuromuscular Blockade, Costs, Atropine, Sugammadex, Glycopyrrolate, Neostigmine, Anesthesia
Interventions
Choice of reversal agent (sugammadex or neostigmine [with muscaranic antagonist])
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
70,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Sep 3, 2026, 2:01 PM EDT
Completed Not applicable Interventional

Anesthetics in Rhytidoplasty - A Comparison Study

NCT02410460
View directory record Official record
Conditions
Rhytidoplasty
Interventions
clonidine, glycopyrrolate, propofol, ketamine, marcaine, scopolamine, midazolam, ondansetron, metoclopramide, lidocaine, famotidine, desflurane, sevoflurane
Drug · Device
Lead sponsor
Mercy Facial Plastic Surgery Center
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 6, 2015 · Synced Sep 3, 2026, 2:01 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Transdermal Administration by a Novel Wireless Iontophoresis Device

NCT06351852
View directory record Official record
Conditions
Spinal Cord Injuries, Constipation, Fecal Incontinence, Neurogenic Bowel
Interventions
Combination of Neostigmine and Glycopyrrolate, I-Box by Dynatronics
Drug · Device
Lead sponsor
James J. Peters Veterans Affairs Medical Center
Federal
Eligibility
18 Years to 89 Years
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Sep 16, 2025 · Synced Sep 3, 2026, 2:01 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

PK Study of PT003 and PT001 in Japanese Healthy Subjects

NCT02196714
View directory record Official record
Conditions
COPD
Interventions
Glycopyrronium and Formoterol Fumarate (GFF) Dose 1, Glycopyrronium and Formoterol Fumarate (GFF) Dose 2, Glycopyrronium (GP) Dose 1, Glycopyrronium (GP) Dose 2
Drug
Lead sponsor
Pearl Therapeutics, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 25, 2017 · Synced Sep 3, 2026, 2:01 PM EDT
Completed Phase 3 Interventional Results available

Multi-Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD (PINNACLE 2)

NCT01854658
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
GFF MDI (PT003), GP MDI (PT001), FF MDI (PT005), Placebo
Drug
Lead sponsor
Pearl Therapeutics, Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
1,615 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
113
States / cities
Birmingham, Alabama • Florence, Alabama • Jasper, Alabama + 110 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2017 · Synced Sep 3, 2026, 2:01 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics of Neostigmine and Glycopyrrolate

NCT04027972
View directory record Official record
Conditions
Spinal Cord Injuries, Constipation, Fecal Incontinence, Neurogenic Bowel
Interventions
Combination of Neostigmine and Glycopyrrolate, I-Box by Dynatronics
Drug · Device
Lead sponsor
James J. Peters Veterans Affairs Medical Center
Federal
Eligibility
18 Years to 70 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Sep 16, 2025 · Synced Sep 3, 2026, 2:01 PM EDT
Completed Phase 4 Interventional Results available

Sugammadex To IMprove Bowel Function

NCT04546672
View directory record Official record
Conditions
Bowel Dysfunction, Postoperative Complications, Neuromuscular Blockade
Interventions
Sugammadex, Neostigmine
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 28, 2024 · Synced Sep 3, 2026, 2:01 PM EDT
Completed Phase 4 Interventional

The Impact of Sugammadex on Ileus After Abdominal Wall Reconstruction

NCT05985343
View directory record Official record
Conditions
Hernia, Ventral, Ileus
Interventions
Neostigmine / Glycopyrrolate, Sugammadex
Drug
Lead sponsor
Clayton Petro
Other
Eligibility
18 Years and older
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 20, 2025 · Synced Sep 3, 2026, 2:01 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Evaluation of Closed-loop TIVA Propofol, Sufentanil and Ketamine Guided by BIS Monitor

NCT01942356
View directory record Official record
Conditions
Acute Cholecystitis, Chronic Cholecystitis
Interventions
TIVA - Hypotension, TIVA - Hypertension, TIVA - Bradycardia, TIVA - Tachycardia, INH - Hypotension, INH - Hypertension, INH - Bradycardia, INH - Tachycardia
Procedure
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 65 Years
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 26, 2015 · Synced Sep 3, 2026, 2:01 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Trial of 12 Weeks of Treatment With Nebulized SUN-101 in Patients With COPD

NCT02347761
View directory record Official record
Conditions
COPD
Interventions
SUN-101 50 mcg BID eFlow (CS) nebulizer, SUN-101 25 mcg BID eFlow (CS) nebulizer, Placebo BID eFlow Closed System (CS) nebulizer
Drug
Lead sponsor
Sunovion Respiratory Development Inc.
Industry
Eligibility
40 Years and older
Enrollment
653 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
44
States / cities
Anniston, Alabama • Phoenix, Arizona • Tempe, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2018 · Synced Sep 3, 2026, 2:01 PM EDT
Completed No phase listed Observational

A Comparative Effectiveness Study of Mortality Outcomes and Related Cardiopulmonary Events Among a Cohort of Chronic Obstructive Pulmonary Disease (COPD) Patients Who Initiate Breztri and Multiple Inhaler Triple Therapy (MITT) in the United States (US)

NCT06744374
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
BGF, MITT
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years and older
Enrollment
22,369 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Wilmington, Delaware
Source: ClinicalTrials.gov public record
Updated Aug 26, 2025 · Synced Sep 3, 2026, 2:01 PM EDT
Completed Phase 4 Interventional Results available

Sugammadex vs. Neostigmine for Neuromuscular Blockade Reversal in Thoracic Surgical Patients

NCT03168308
View directory record Official record
Conditions
Neuromuscular Blockade
Interventions
Sugammadex, Neostigmine w/ Glycopyrrolate
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 3, 2020 · Synced Sep 3, 2026, 2:01 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Trial of 12 Weeks of Treatment With Nebulized SUN-101 in Patients With COPD (GOLDEN-4)

NCT02347774
View directory record Official record
Conditions
COPD, Chronic Obstructive Pulmonary Disease
Interventions
SUN-101 50 mcg BID eFlow (CS) nebulizer, SUN-101 25 mcg BID eFlow (CS) nebulizer, Placebo eFlow (CS) nebulizer
Drug
Lead sponsor
Sunovion Respiratory Development Inc.
Industry
Eligibility
40 Years and older
Enrollment
641 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
45
States / cities
Andalusia, Alabama • Jasper, Alabama • Glendale, Arizona + 40 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2018 · Synced Sep 3, 2026, 2:01 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of NVA237 in Patients With Chronic Obstructive Pulmonary Disease (COPD)

NCT01119950
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
NVA237 12.5 µg once daily, NVA237 25.0 µg once daily, NVA237 12.5 µg twice daily, NVA237 50.0 µg once daily, NVA237 25.0 µg twice daily, NVA237 100.0 µg once daily, NVA237 50.0 µg twice daily, Placebo to NVA237 once daily
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years and older
Enrollment
388 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
6
States / cities
Anniston, Alabama • San Diego, California • Torrance, California + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2015 · Synced Sep 3, 2026, 2:01 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Use of a Prokinetic Agent as an Adjunct to Thrice Weekly Bowel Care After SCI

NCT04671030
View directory record Official record
Conditions
Spinal Cord Injuries, Constipation, Neurogenic Bowel
Interventions
Neostigmine and Glycopyrrolate, Iontophoresis
Drug · Device
Lead sponsor
James J. Peters Veterans Affairs Medical Center
Federal
Eligibility
18 Years to 75 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Dec 29, 2021 · Synced Sep 3, 2026, 2:01 PM EDT
Completed Phase 2 Interventional Results available

A Dose-Ranging Study of the Effect of Glycopyrrolate in Subjects With Axillary Hyperhidrosis

NCT02016885
View directory record Official record
Conditions
Hyperhidrosis
Interventions
glycopyrrolate, 1.0%, glycopyrrolate, 2.0%, glycopyrrolate, 3.0%, glycopyrrolate, 4.0%, Vehicle
Drug · Other
Lead sponsor
Journey Medical Corporation
Industry
Eligibility
18 Years and older
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
21
States / cities
Hot Springs, Arkansas • Little Rock, Arkansas • Encinitas, California + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2021 · Synced Sep 3, 2026, 2:01 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Use of Sugammadex for Reversal of Paralysis in Microlaryngoscopy

NCT03111121
View directory record Official record
Conditions
Microlaryngoscopy, Rigid Bronchoscopy
Interventions
Sugammadex, neostigmine, glycopyrrolate
Drug
Lead sponsor
West Virginia University
Other
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Jul 19, 2025 · Synced Sep 3, 2026, 2:01 PM EDT
Completed Phase 2 Interventional Results available

Comparator Study of the Effect of Glycopyrrolate and Glycopyrronium in Subjects With Axillary Hyperhidrosis

NCT02129660
View directory record Official record
Conditions
Hyperhidrosis
Interventions
Dose 1 of glycopyrrolate, 2.0% QD, Dose 2 of glycopyrrolate, 3.0% QD, Dose 1 of glycopyrronium, 2.5% QD, Dose 2 of glycopyrronium, 3.75% QD, Vehicle
Drug · Other
Lead sponsor
Journey Medical Corporation
Industry
Eligibility
18 Years to 99 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
14
States / cities
Encinitas, California • Fremont, California • Tampa, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2025 · Synced Sep 3, 2026, 2:01 PM EDT
Completed Phase 3 Interventional Results available

RETHINC: REdefining THerapy In Early COPD for the Pulmonary Trials Cooperative

NCT02867761
View directory record Official record
Conditions
COPD (Chronic Obstructive Pulmonary Disease)
Interventions
Indacaterol/Glycopyrrolate, Placebo
Drug
Lead sponsor
University of Michigan
Other
Eligibility
40 Years to 80 Years
Enrollment
780 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
16
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2023 · Synced Sep 3, 2026, 2:01 PM EDT